Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

G2295

Sigma-Aldrich

Glimepirid

≥98% (HPLC), solid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C24H34N4O5S
CAS-Nummer:
93479-97-1
Molekulargewicht:
490.62
MDL-Nummer:
MFCD00878417
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24895093
NACRES:
NA.77

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

solid

Farbe

white

mp (Schmelzpunkt)

212.2-214.5 °C

Löslichkeit

DMSO: >10 mg/mL

Ersteller

Sanofi Aventis

Lagertemp.

room temp

SMILES String

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChIKey

WIGIZIANZCJQQY-RUCARUNLSA-N

Angaben zum Gen

human ... ABCC8(6833) , KCNJ1(3758) , KCNJ11(3767)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.

Anwendung

Glimepiride has been used:
  • as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)
  • as a sulfonylurea ATP-sensitive potassium channel (KATP) channel inhibitor in breast cancer MDA-MB-231 cells
  • in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion

Glimepirid wird derzeit zur Behandlung von Typ-2-Diabetes eingesetzt.

Biochem./physiol. Wirkung

Glimepirid ist ein wirksamer Blocker kardialer KATP-Kanäle, aktiviert durch Pinacidil mit einem IC50 von 6,8 nM.
Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.

Leistungsmerkmale und Vorteile

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Health hazard
GHS08

Signalwort

Warning

H-Sätze

H361

Gefahreneinstufungen

Repr. 2

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 8

1 of 8

Glimepirid für die Systemeignung European Pharmacopoeia (EP) Reference Standard

Y0000516

Glimepirid für die Systemeignung

Gliclazid British Pharmacopoeia (BP) Reference Standard

BP368

Gliclazid

USP

USP

1292347

Glimepirid-verwandte Verbindung D

vibrant-m

Y0001742

Glimepirid für die Identifizierung von Unreinheit A

Gliclazid European Pharmacopoeia (EP) Reference Standard

G0326000

Gliclazid

Glipizid European Pharmacopoeia (EP) Reference Standard

G0340000

Glipizid

Glybenclamid ≥99% (HPLC)

Sigma-Aldrich

G0639

Glybenclamid

USP

USP

1292336

Glimepirid-verwandte Verbindung C

Li-Ping Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)
By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This
A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG
Tiwari A, et al.
International Journal of Advanced Research , 4, 920-927 (2016)
W Rathmann et al.
Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)
To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;
Lan Gao et al.
International journal of technology assessment in health care, 28(4), 436-444 (2012-09-26)
The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population. The
William T Cefalu et al.
Lancet (London, England), 382(9896), 941-950 (2013-07-16)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with
Alle zugehörigen Dokumente anzeigen

Artikel

Insulin Signaling and Energy Homeostasis

Glucose metabolism is regulated by the opposing actions of insulin and glucagon. Insulin is released from pancreatic ß cells in response to high blood glucose levels and regulates glucose metabolism through its actions on muscle, liver, and adipose tissue.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.